BR112023021133A2 - Receptores quiméricos de antígenos para direcionar cânceres positivos para cd5 - Google Patents
Receptores quiméricos de antígenos para direcionar cânceres positivos para cd5Info
- Publication number
- BR112023021133A2 BR112023021133A2 BR112023021133A BR112023021133A BR112023021133A2 BR 112023021133 A2 BR112023021133 A2 BR 112023021133A2 BR 112023021133 A BR112023021133 A BR 112023021133A BR 112023021133 A BR112023021133 A BR 112023021133A BR 112023021133 A2 BR112023021133 A2 BR 112023021133A2
- Authority
- BR
- Brazil
- Prior art keywords
- specific
- chimeric antigen
- targeting
- positive cancers
- antigen receptors
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title abstract 2
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000000822 natural killer cell Anatomy 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464436—Cytokines
- A61K39/46444—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/11—Antigen recognition domain
- A61K2239/13—Antibody-based
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/17—Hinge-spacer domain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/21—Transmembrane domain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/22—Intracellular domain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/28—Expressing multiple CARs, TCRs or antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
receptores quiméricos de antígenos para direcionar cânceres positivos para cd5. a presente invenção refere-se a métodos e composições relacionadas ao direcionamento de células que expressam cd5 com receptores específicos modificados. em modalidades específicas, as células nk são especificamente projetadas para se ligarem ao antígeno cd5 usando construtos específicas de receptor quimérico de antígeno. em certas modalidades, os vetores que expressam os cars direcionados a cd5 também expressam um gene suicida específico e/ou uma ou mais citocinas específicas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163174990P | 2021-04-14 | 2021-04-14 | |
PCT/US2022/024842 WO2022221548A1 (en) | 2021-04-14 | 2022-04-14 | Chimeric antigen receptors to target cd5-positive cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023021133A2 true BR112023021133A2 (pt) | 2023-12-12 |
Family
ID=83640731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023021133A BR112023021133A2 (pt) | 2021-04-14 | 2022-04-14 | Receptores quiméricos de antígenos para direcionar cânceres positivos para cd5 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20240189357A1 (pt) |
EP (1) | EP4322992A1 (pt) |
JP (1) | JP2024514203A (pt) |
KR (1) | KR20240007911A (pt) |
CN (1) | CN117480187A (pt) |
AU (1) | AU2022259658A1 (pt) |
BR (1) | BR112023021133A2 (pt) |
CA (1) | CA3216557A1 (pt) |
IL (1) | IL307408A (pt) |
MX (1) | MX2023012180A (pt) |
WO (1) | WO2022221548A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202330586A (zh) * | 2021-10-20 | 2023-08-01 | 美國德州系統大學評議委員會 | 具最佳信號之car構築體之工程化nk細胞 |
WO2023070079A1 (en) * | 2021-10-21 | 2023-04-27 | Board Of Regents, The University Of Texas System | Methods for production of therapeutic immune cells having enhanced metabolic fitness and compositions thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016274989A1 (en) * | 2015-06-12 | 2017-11-02 | Immunomedics, Inc. | Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs |
US20230159618A1 (en) * | 2017-07-25 | 2023-05-25 | Board Of Regents, The University Of Texas System | Enhanced chimeric antigen receptors and use thereof |
CN111432823A (zh) * | 2017-07-25 | 2020-07-17 | 得克萨斯大学体系董事会 | 增强的嵌合抗原受体及其用途 |
-
2022
- 2022-04-14 BR BR112023021133A patent/BR112023021133A2/pt unknown
- 2022-04-14 EP EP22788946.6A patent/EP4322992A1/en active Pending
- 2022-04-14 CA CA3216557A patent/CA3216557A1/en active Pending
- 2022-04-14 US US18/552,727 patent/US20240189357A1/en active Pending
- 2022-04-14 CN CN202280042176.6A patent/CN117480187A/zh active Pending
- 2022-04-14 JP JP2023563211A patent/JP2024514203A/ja active Pending
- 2022-04-14 KR KR1020237039102A patent/KR20240007911A/ko unknown
- 2022-04-14 AU AU2022259658A patent/AU2022259658A1/en active Pending
- 2022-04-14 WO PCT/US2022/024842 patent/WO2022221548A1/en active Application Filing
- 2022-04-14 MX MX2023012180A patent/MX2023012180A/es unknown
- 2022-04-14 IL IL307408A patent/IL307408A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2022259658A1 (en) | 2023-11-23 |
CN117480187A (zh) | 2024-01-30 |
MX2023012180A (es) | 2024-01-05 |
JP2024514203A (ja) | 2024-03-28 |
WO2022221548A1 (en) | 2022-10-20 |
IL307408A (en) | 2023-12-01 |
CA3216557A1 (en) | 2022-10-20 |
EP4322992A1 (en) | 2024-02-21 |
US20240189357A1 (en) | 2024-06-13 |
KR20240007911A (ko) | 2024-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112023021133A2 (pt) | Receptores quiméricos de antígenos para direcionar cânceres positivos para cd5 | |
AU2018258045A1 (en) | Chimeric antibody/T-cell receptor constructs and uses thereof | |
PH12020552138A1 (en) | Bcma chimeric antigen receptors and uses thereof | |
BR112019007288A2 (pt) | proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente | |
PE20210256A1 (es) | Anticuerpos anti-lag3 | |
MX2020012445A (es) | Receptores de antigeno quimericos con dominios enlazadores modificados y usos de los mismos. | |
BR112012010698A2 (pt) | método para tratamento de um sujeito com câncer, método de triagem de uma célula de câncer de mama, e , anticorpo | |
CL2017001866A1 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
MY194628A (en) | Antibody/t-cell receptor chimeric constructs and uses thereof | |
PE20181013A1 (es) | Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3 | |
BR112018001530A2 (pt) | anticorpo biespecífico, polinucleotídeo, vetor, célula hospedeira, métodos para produzir o anticorpo biespecífico e de inibição do crescimento de células tumorais e composição farmacêutica | |
AU2016245958A8 (en) | CD20 therapies, CD22 therapies, and combination therapies with a CD19 Chimeric Antigen Receptor (CAR) - expressing cell | |
MX2013007392A (es) | Anticuerpo modificado con vida media mejorada. | |
BR112021016984A2 (pt) | Receptores de antígeno quimérico direcionados a dll3 e agentes de ligação | |
CL2012002433A1 (es) | Anticuerpo aislado o fragmento inmunoreactivo del mismo que comprende un dominio variable que se une específicamente a un dominio extracelular del receptor b7-h3; ácido nucleico que lo codifica; hibridoma que lo secreta; reactivo de redireccionamiento de doble afinidad (dart) que lo comprende; composición farmacéutica que lo comprende; y su uso para tratar cáncer. | |
CL2019000119A1 (es) | Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123. | |
BR112021021843A8 (pt) | Composições de proteínas de fusão quiméricas modificadas e método de uso das mesmas | |
PE20130207A1 (es) | Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones | |
CL2012000254A1 (es) | Anticuerpo aislado de unión a antígeno que se une a proteína atenuante de linfocitos b y t (btla); ácido nucleico que lo codifica; composición que comprende a dicho anticuerpo; y vector de expresión. | |
BRPI0812878B8 (pt) | anticorpo isolado ou parte funcional do mesmo, vetor, método para produzir um anticorpo ou uma parte funcional do mesmo, para produzir uma célula produtora de anticorpo e para produzir um anticorpo capaz de se ligar especificamente a rsv, composição, e, uso de um anticorpo ou parte funcional do mesmo ou de uma composição ou de vetor | |
CR10652A (es) | Anticuerpos monoclonales humanos especificos para light humano antagonistas | |
UA99339C2 (ru) | Антитело, которое специфично связывает человеческий tyrp1 | |
BR112012010266A2 (pt) | anticorpo anti-fractalquina ou fragmento de ligação a fkn do mesmo, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, métodos para preparar um anticorpo anti-fractalquina ou fragmento de ligação a fkn do mesmo, e para tratar um distúrbio inflamatório, e, uso de um anticorpo ou fragmento de ligação a fkn do mesmo | |
ZA202201464B (en) | Anti-tigit antibodies and application thereof | |
MX2019013370A (es) | Constructos de anticuerpos de ácidos nucleicos optimizados. |